TY - JOUR
T1 - Traction Bronchiectasis/Bronchiolectasis on CT Scans in Relationship to Clinical Outcomes and Mortality
T2 - The COPDGene Study
AU - the COPDGene Investigators
AU - Hata, Akinori
AU - Hino, Takuya
AU - Putman, Rachel K.
AU - Yanagawa, Masahiro
AU - Hida, Tomoyuki
AU - Menon, Aravind A.
AU - Honda, Osamu
AU - Yamada, Yoshitake
AU - Nishino, Mizuki
AU - Araki, Tetsuro
AU - Valtchinov, Vladimir I.
AU - Jinzaki, Masahiro
AU - Honda, Hiroshi
AU - Ishigami, Kousei
AU - Johkoh, Takeshi
AU - Tomiyama, Noriyuki
AU - Christiani, David C.
AU - Lynch, David A.
AU - Estépar, Raúl San José
AU - Washko, George R.
AU - Cho, Michael H.
AU - Silverman, Edwin K.
AU - Hunninghake, Gary M.
AU - Hatabu, Hiroto
N1 - Funding Information:
R.K.P. supported by the National Institutes of Health (NIH) (grant no. K08 HL140087). M.Y. supported by Japan Society for the Promotion of Science KAKENHI (grant nos. JP21K07672, JP21H03840, and JP20gk0110051). M.N. supported by NIH (grant nos. R01CA203636, U01CA209414, R01HL111024, and R01CA240592). D.C.C. supported by the NIH (grant no. U01CA209414). D.A.L. supported by National Heart, Lung, and Blood Institute for COPDGene (grant nos. U01 HL089897 and U01 HL089856). R.S.J.E. supported by the NIH. G.R.W. supported by National Heart, Lung, and Blood Institute (grant nos. R01 HL116473 and R01 HL122464). M.H.C. supported by National Heart, Lung, and Blood Institute (grant nos. R01HL149861, R01HL135142, R01HL137927, and R01HL147148). E.S. supported by NIH (grant nos. U01HL089897 and U01 HL089856). G.M.H. supported by NIH (grant nos. RO1HL111024, R01HL130974, and R01HL135142). H. Hatabu supported by the NIH (grant nos. R01CA203636, 5U01CA209414, and R01HL135142) and National Heart, Lung, and Blood Institute (grant nos. 2R01HL111024 and 1R01HL130974). COPDGene is also supported by the COPD Foundation through contributions made to an industry advisory board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.
Funding Information:
Disclosures of conflicts of interest: A.H. No relevant relationships. T. Hino No relevant relationships. R.K.P. No relevant relationships. M.Y. No relevant relationships. T. Hida No relevant relationships. A.A.M. No relevant relationships. O.H. No relevant relationships. Y.Y. No relevant relationships. M.N. Institutional research grant from Canon Medical Systems, AstraZeneca, and Daiichi Sankyo; consulting fees from AstraZeneca, Daiichi Sankyo; T.A. No relevant relationships. V.I.V. No relevant relationships. M.J. No relevant relationships. H. Honda No relevant relationships. K.I. No relevant relationships. T.J. No relevant relationships. N.T. No relevant relationships. D.C.C. No relevant relationships. D.A.L. No relevant relationships. R.S.J.E. Equity stock holder in Quantitative Imaging Solutions. G.R.W. Investigator-initiated research award from Boehringer Ingelheim; consulting fees from Novartis, Janssen Pharmaceuticals, Philips, Vertex; support for attending meetings and/or travel from Philips, Vertex; participation on a Data Safety Monitoring Board or Advisory Board from Pulmonx; cofounder and equity shareholder of Quantitative Imaging Solutions. M.H.C. Grants or contracts from Bayer, GlaxoSmithKline; consulting fees from AstraZeneca; payment or honoraria for lectures from Illumina. E.K.S. Grants or contracts from Bayer, GlaxoSmithKline. G.M.H. Consulting fees from Boehringer-Ingelheim, Gerson Lehrman Group; will serve on Data Safety Monitoring Board for Biogen. H. Hatabu Grant support from Canon Medical Systems and Konica-Minolta; consulting fees from Mitsubishi Chemical, Canon Medical Systems.
Publisher Copyright:
© RSNA, 2022.
PY - 2022/9
Y1 - 2022/9
N2 - Background: The clinical impact of interstitial lung abnormalities (ILAs) on poor prognosis has been reported in many studies, but risk stratification in ILA will contribute to clinical practice. Purpose: To investigate the association of traction bronchiectasis/bronchiolectasis index (TBI) with mortality and clinical outcomes in individuals with ILA by using the COPDGene cohort. Materials and Methods: This study was a secondary analysis of prospectively collected data. Chest CT scans of participants with ILA for traction bronchiectasis/bronchiolectasis were evaluated and outcomes were compared with participants without ILA from the COPDGene study (January 2008 to June 2011). TBI was classified as follows: TBI-0, ILA without traction bronchiectasis/bronchiolectasis; TBI-1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion; TBI-2, ILA with mild to moderate traction bronchiectasis; and TBI-3, ILA with severe traction bronchiectasis and/or honeycombing. Clinical outcomes and overall survival were compared among the TBI groups and the non-ILA group by using multivariable linear regression model and Cox proportional hazards model, respectively. Results: Overall, 5295 participants (median age, 59 years; IQR, 52–66 years; 2779 men) were included, and 582 participants with ILA and 4713 participants without ILA were identified. TBI groups were associated with poorer clinical outcomes such as quality of life scores in the multivariable linear regression model (TBI-0: coefficient, 3.2 [95% CI: 0.6, 5.7; P = .01]; TBI-1: coefficient, 3.3 [95% CI: 1.1, 5.6; P = .003]; TBI-2: coefficient, 7.6 [95% CI: 4.0, 11; P , .001]; TBI-3: coefficient, 32 [95% CI: 17, 48; P , .001]). The multivariable Cox model demonstrated that ILA without traction bronchiectasis (TBI-0–1) and with traction bronchiectasis (TBI-2–3) were associated with shorter overall survival (TBI-0–1: hazard ratio [HR], 1.4 [95% CI: 1.0, 1.9; P = .049]; TBI-2–3: HR, 3.8 [95% CI: 2.6, 5.6; P , .001]). Conclusion: Traction bronchiectasis/bronchiolectasis was associated with poorer clinical outcomes compared with the group without interstitial lung abnormalities; TBI-2 and 3 were associated with shorter survival.
AB - Background: The clinical impact of interstitial lung abnormalities (ILAs) on poor prognosis has been reported in many studies, but risk stratification in ILA will contribute to clinical practice. Purpose: To investigate the association of traction bronchiectasis/bronchiolectasis index (TBI) with mortality and clinical outcomes in individuals with ILA by using the COPDGene cohort. Materials and Methods: This study was a secondary analysis of prospectively collected data. Chest CT scans of participants with ILA for traction bronchiectasis/bronchiolectasis were evaluated and outcomes were compared with participants without ILA from the COPDGene study (January 2008 to June 2011). TBI was classified as follows: TBI-0, ILA without traction bronchiectasis/bronchiolectasis; TBI-1, ILA with bronchiolectasis but without bronchiectasis or architectural distortion; TBI-2, ILA with mild to moderate traction bronchiectasis; and TBI-3, ILA with severe traction bronchiectasis and/or honeycombing. Clinical outcomes and overall survival were compared among the TBI groups and the non-ILA group by using multivariable linear regression model and Cox proportional hazards model, respectively. Results: Overall, 5295 participants (median age, 59 years; IQR, 52–66 years; 2779 men) were included, and 582 participants with ILA and 4713 participants without ILA were identified. TBI groups were associated with poorer clinical outcomes such as quality of life scores in the multivariable linear regression model (TBI-0: coefficient, 3.2 [95% CI: 0.6, 5.7; P = .01]; TBI-1: coefficient, 3.3 [95% CI: 1.1, 5.6; P = .003]; TBI-2: coefficient, 7.6 [95% CI: 4.0, 11; P , .001]; TBI-3: coefficient, 32 [95% CI: 17, 48; P , .001]). The multivariable Cox model demonstrated that ILA without traction bronchiectasis (TBI-0–1) and with traction bronchiectasis (TBI-2–3) were associated with shorter overall survival (TBI-0–1: hazard ratio [HR], 1.4 [95% CI: 1.0, 1.9; P = .049]; TBI-2–3: HR, 3.8 [95% CI: 2.6, 5.6; P , .001]). Conclusion: Traction bronchiectasis/bronchiolectasis was associated with poorer clinical outcomes compared with the group without interstitial lung abnormalities; TBI-2 and 3 were associated with shorter survival.
UR - http://www.scopus.com/inward/record.url?scp=85137008074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137008074&partnerID=8YFLogxK
U2 - 10.1148/radiol.212584
DO - 10.1148/radiol.212584
M3 - Article
C2 - 35638925
AN - SCOPUS:85137008074
SN - 0033-8419
VL - 304
SP - 694
EP - 701
JO - Radiology
JF - Radiology
IS - 3
ER -